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Abstract 
Nucleophosmin (NPM1) gene mutations resulting in cytoplasmic delocalization of Nucleo-
phosmin (NPMc+) are the most common genetic alteration in acute myeloid leukemia (AML). 
Here, we attempted to prepare monoclonal antibodies (mAbs) against NPM1 mutation A 
(NPM-mA) and investigated the mAbs’ clinical utility in immunohistochemical detection of 
NPMc+AML.  The  pET-32a-NPM-mA  vector  with  the  whole  open  reading  frame  of  the 
NPM-mA gene was constructed. E.coli BL21 transformed with the vector were induced to 
express the NPM-mA recombinant protein. BALB/c mice were immunized with the recom-
binant NPM-mA. Positive clones were selected by indirect ELISA and the mAbs were ob-
tained. Immunohistochemistry was performed to detect the NPMc+ in bone marrow smears 
from 10 AML patients with NPM-mA. The results showed that the pET-32a-NPM-mA vector 
was successfully constructed and the NPM-mA recombinant protein was used to immunize 
the mice. Two positive clones (2G3 and 3F9) were selected. The mAbs against NPM-mA were 
raised, but did cross-react with wild type NPM1. The mAbs can be used to detect the cyto-
plasmic dislocation of NPM1 in all AMLs carrying NPM-mA.  Our results show that an-
ti-NPM-mA mAbs were produced. Though they would cross-react with wild type NPM1, the 
mAbs may still have potential in the detection of NPMc+AMLs. 
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1. Introduction 
Nucleophosmin (NPM1) is an ubiquitously ex-
pressed  nucleo-cytoplasmic  shuttling  protein  with 
prominent  nucleolar  localization  [1,  2].  Previous 
studies  have  demonstrated  that  mutations  of  the 
NPM1  gene  leading  to  aberrant  cytoplasmic  NPM1 
expression (NPMc+) occur in about one-third of acute 
myeloid leukemias (AML) and 45% to 64% of AML 
with normal karyotype cases [3, 4]. The most common 
molecular variant of the NPM1 gene is mutation A, 
accounting for about 75-85% of cases. It is due to a 
duplication  of  TCTG  tetranucleotide  at  the 
C-terminus of the NPM1 gene, which generates a nu-
clear export signal (NES) motif responsible for cyto-
plasmic accumulation of NPM1 [5-7]. Many observa-
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tions indicate that the NPM1 mutation A (NPM-mA) 
is not only an AML-specific genetic event, but also 
remains stable during the course of the disease [6, 8, 
9].  Meanwhile,  the  AML  with  cytoplasmic  NPM1 
(NPMc+AML)  exhibits  distinctive  biological  and 
clinical features and has been included as a new pro-
visional entity in the 2008 World Health Organization 
(WHO) classification of myeloid neoplasms [5, 10-13]. 
Thus, the analysis of NPM1 mutations may emerge as 
an initial screening step in the diagnostic/prognostic 
work-up  of  AML  and  could  also  serve  to  monitor 
minimal residual disease (MRD) [14]. 
Over the past five years, several qualitative and 
quantitative molecular  assays for  identifying  NPM1 
mutations have been developed. Currently available 
screening  of  NPM1  mutations  using  conventional 
polymerase chain reaction (PCR) followed by capil-
lary  electrophoresis  is  rather  time-consuming,  tech-
nical-demanding  and  laborious  [15].  Alternatively, 
the  simple,  inexpensive  and  specific  immunohisto-
chemical tests (IHC) which indirectly detect aberrant 
cytoplasmic  accumulation  of  NPM1  proteins  can 
serve as a surrogate to molecular studies [16-18]. To 
popularize  IHC  detection  of  cytoplasmic  NPM1  in 
clinical diagnosis/prognosis of NPMc+AML, we need 
to prepare the anti-NPM-mA monoclonal antibodies 
(mAbs) as the primary antibody in IHC assay. 
In 1999, Cordell et al prepared the first panel of 
mAbs associated with NPM1 protein, two of which 
recognized the N-terminal portion of NPM1 present 
in NPM-ALK fusion protein and the third was specific 
for wild-type NPM1 (NPM-wt). Their main purpose 
was to detect the NPM-ALK fusion protein created by 
the  t(2;5)  chromosomal  translocation  in  anaplastic 
large-cell lymphoma (ALCL) [19]. Nowadays, exten-
sive detection of cytoplasmic dislocation of NPM1 by 
IHC  has  been  performed  using  aspecific  antibodies 
that bind both the NPM-wt and NPM-mA proteins. In 
IHC assay labeling with this kind of mAbs, the cyto-
plasmic subcellular localization of NPM1 may not be 
closely associated with NPM1 gene mutations proba-
bly because of NPM1 diffusion during the tissue fixa-
tion and the influence of fixatives [20]. Thus, produc-
tion of anti-NPM-mA mAbs for routine diagnostic of 
NPMc+AML is of critical importance. 
To date, most detections of cytoplasmic NPM1 
by IHC have been carried out in bone marrow biop-
sies.  However,  not  all  hematological  centers,  espe-
cially  in  developing  countries,  adopt  bone  marrow 
biopsy as a frontline diagnostic procedure for AML. 
Hence,  the  ability  to  detect  cytoplasmic  NPM1  on 
bone marrow smears would be advantageous. In view 
of this, we attempted to produce the mAbs that were 
specific  for  NPM-mA  protein  and  preliminarily  ex-
plore the application of IHC labeling with these mAbs 
on bone marrow smears of AML patients with NPM1 
mutations. 
2. Materials and Methods 
2.1 PCR for amplification of NPM-mA gene 
According  to  the  published  sequence  of  the 
NPM-mA in GenBank (no.AY740634), a pair of spe-
cific  primers  were  designed  to  amplify  the  ORF  of 
NPM-mA  gene  from  pEGFP-C1-NPM-mA  vectors, 
which were kindly provided by Dr. B Falini (Institute 
of Hematology, University of Perugia, Perugia, Italy). 
The  forward  and  backward  primers  were: 
5’-CGGGATCCATCGAAGGTCGTGAAGATTCGAT
GGACAT-3’,  and  5’-CGCGCGACCGAGCGGAA 
GCTTCTATTTTCTTAAAGAGAC-3’.  Underlined 
nucleotides represent the BamH  I and Hind III site, 
respectively.  PCR  conditions  included 
pre-denaturation at 98°C for 5 min; 32 cycles of de-
naturation at 98°C for 20 sec, annealing at 56°C for 20 
sec, and extension at 72°C for 80 sec; followed by a 
final extension at 72°C for 5 min. 
2.2 Construction of expressing vector 
pET-32a-NPM-mA 
After  being  checked  by  using  1%  agarose  gel 
electrophoresis and retrieved utilizing the MinElute 
Gel Extration Kit (Tiangen, Beijing, China), the ampli-
fication products (NPM-mA gene) were cloned into 
the BamH I and Hind III site of the pET-32a plasmids 
creating  fusion  vectors  pET-32a-NPM-mA  in  the 
presence of T4 DNA Ligase (TaKara, Tokyo, Japan). 
The  fusion  vectors  were  subsequently  transformed 
into  E.  coli  DH5α  cloning  vectors  and  E.  coli  BL21 
(DE3) expression bacteria and then grown overnight 
at 37°C in Luria-Bertani (LB) medium with ampicillin 
(100  μg/ml).  The  positive  expression  clones  were 
screened  out  by  colony  PCR.  After  extracted  by  a 
commercial  kit  (Huashun,  Shanghai,  China), 
pET-32a-NPM-mA  was  further  identified  by  re-
striction  enzyme  digestions  and  DNA  sequencing 
(Invitrogen,  Shanghai,  China).  The  positive  expres-
sion  BL21  (DE3)  was  stored  in  LB  containing  15% 
glycerine at -80°C. 
2.3 Expression and Purification of NPM-mA 
protein 
Overnight  culture  of  pET-32a-NPM-mA  trans-
formed  BL21  (1  ml)  was  inoculated  to  1000  ml 
LB/amp and cultured at 37°C for 3-4 h at 200 rpm 
until  OD600  reached  0.3-0.4,  then  0.1  mM  IPTG 
(TaKara, Tokyo, Japan) was added to induce protein 
expression. The culture was incubated for 4 h at 37°C 
at 200 rpm before harvesting the cells by centrifuga-Int. J. Med. Sci. 2011, 8 
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tion (15,000×g, 20 min, 4°C) and the cell pellets were 
washed and lysed by sonication on ice. After centri-
fuged  at  15,000×g  for  20  min,  the  supernatant  was 
analyzed by SDS-PAGE as the soluble fraction and the 
remaining cell pellet as the insoluble fraction to de-
termine  whether  native  or  denaturing  conditions 
were necessary for protein purification. The superna-
tant  was  loaded  to  His-Bind-Resins  affinity  column 
(Novagen, Darmstadt, Germany) to purify the fusion 
protein.  The  purified  protein  was  dialysed  against 
phosphate-buffered saline (PBS) overnight at 4°C and 
stored  at  -80°C  before  analyzed  by  SDS-PAGE  and 
quantitated by using the BCA Protein Assay Kit (Be-
yotime, Shanghai, China). 
2.4 Immunizations 
Five-week old female BALB/c mice initially re-
ceived  subcutaneous  injection  of  purified  NPM-mA 
fusion protein (100 μg) emulsified in an equal volume 
of Freund’s complete adjuvant (Sigma, St. Luis, MO, 
USA).  A  second  injection  of  the  same  dose  of 
NPM-mA  protein  in  incomplete  Freund’s  adjuvant 
was administered 2 weeks later. 10-14 days after the 
second booster, the mice were then given NPM-mA 
fusion protein without adjuvant intraperitoneally. An 
additional intraperitoneal injection of 100 μg of anti-
gen  was  given  2  days  before  harvesting  the  spleen 
cells. Experiments with injected mice were performed 
under the guidelines for care and use of experimental 
animals. 
2.5 Cellular fusions 
When the anti-NPM-mA antibodies titre of mice 
serum  reached  1:1024  checked  by  indirect  en-
zyme-linked immunosorbent assay (ELISA), myeloma 
cells  line  SP2/0  (106)  were  fused  with  splenocytes 
(107)  by  the  addition  of  45%  polyethylene  glycol 
(PEG-4000). Hybridomas were selected in HAT me-
dium  (Gibco,  Carlsbad,  CA,  USA)  and  cultured  in 
96-well plates with BALB/c (8 weeks old) peritoneal 
macrophages cells as feeder cells at 37°C in 5% CO2 in 
air. When single colonies of cells were visualized, cell 
culture supernatants were obtained and screened for 
the presence of anti-NPM-mA antibodies using indi-
rect  ELISA.  Selected  positive  hybridomas  were  ex-
panded and subcloned by limiting dilution. 
2.6 Purification and characterization of mAbs 
After typed by mouse monoclonal antibody iso-
typing kit (Sigma, St. Luis, MO, USA), the prepared 
mAbs were purified from cell-culture supernatant by 
affinity  chromatography.  Indirect  ELISA  was  then 
carried out on NPM-wt and NPM-mA coated plates to 
check the antigenic characterization of mAbs. 
2.7 Patients 
Bone  marrow/peripheral  blood  smears  were 
obtained from de novo AML patients, who were from 
Southwest  Hospital  of  Third  Military  Medical  Uni-
versity and The First Affiliated Hospital of Chongqing 
Medical University (Chongqing, China) between 2008 
and  2009.  Informed  consent  was  obtained  from  all 
patients, and the study was approved by the ethics 
committees of the participating institutions. Ten posi-
tive samples with NPM-mA were selected by direct 
sequencing. 
2.8 Immunohistochemistry 
Slides were incubated with the anti-NPM anti-
body  we  prepared  (1:100  in  Tris-buffered  saline) 
overnight  at  4°C.  Immunohistochemistry  was  per-
formed  using  the  Streptavidin-Peroxidase  (SP)-9000 
kit  (Zhongshan,  Beijing,  China)  according  to  the 
manufacturer’s instructions. Peroxidase activity was 
revealed with 3-3-diaminobenzidine-copper sulphate 
(Sigma,  St.  Luis,  MO,  USA)  to  obtain  brownblack 
granules.  The  subcellular  distribution  of  NPM-mA 
was assessed after counterstained with hematoxylin. 
PBS was used as a negative control for the anti-NPM 
antibody. 
3. Results 
3.1 PCR for amplification of NPM-mA gene 
Using  a  pair  of  primers  specific  for  NPM-mA 
gene, a DNA fragment of approximately 900 bp size 
was  amplified  from  the  pEGFP-C1-NPM-mA  plas-
mids  by  PCR  technique  (Figure  1),  which  corre-
sponded  to  the  full  length  of  open  reading  frame 
(ORF) of the NPM-mA gene (935 bp). 
 
Figure 1. PCR amplifying the full sequence of ORF of the 
NPM-mA gene. The PCR products amplified with a pair of 
primers against the NPM-mA gene were analyzed by 1% 
agarose  gel  electrophoresis.1:  DL2000  markers;  2-3: 
products of PCR. Int. J. Med. Sci. 2011, 8 
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3.2 Construction of recombinant vector 
pET-32a-NPM-mA 
To generate a recombinant human encoding the 
NPM-mA protein, the pET-32a-NPM-mA vector was 
cloned. As shown in Figure 2, the pET-32a-NPM-mA 
vector  was  successfully  constructed  as  verified  by 
bacterial colony PCR (Figure 2A), restriction enzyme 
digestions (Figure 2B) and DNA sequencing (data not 
shown). 
 
 
 
Figure 2. Cloning of the recombinant vector pET-32a-NPM-mA. A, Bacterial colony PCR for the detection of the BL21 
(DE3) clones with the target prokaryotic expression vector pET-32a-NPM-mA. 1-7: 7 colonies of bacteria selected on LB 
medium with ampicillin; 8: DL2000 markers. B, Double endonuclease digestion of the prokaryotic expression vector 
pET-32a-NPM-mA. 1-2: pET-32a-NPM-mA; 3: DL15000 markers; 4: DL2000 markers; 5-6: double digestion with the BamH 
I and Hind III. 
 
 
3.3 Expression and purification of recombinant 
NPM-mA antigen 
The NPM-mA fusion protein was resoluble and 
detected  in  the  culture  supernatants.  SDS-PAGE 
analysis of the fusion protein is displayed in Figure 3. 
Expression and purification of the NPM-mA antigen 
were performed as described in Materials and Meth-
ods.  The  concentration  of  the  purified  recombinant 
protein was 1.95 μg/μl determined by BCA protein 
assay. 
 
Figure 3. SDS-PAGE assay of the purified NPM-mA fusion 
protein. 1: protein size markers; 2-3: recombinant NPM-mA 
fusion protein. 
 
3.4 Production of the anti-NPM mAbs 
For  selecting  the  clones  with  mAbs  against 
NPM-mA,  the  supernatants  of  fused  cells  were  as-
sayed by indirect ELISA. Two clones were found to be 
positive in the ELISA screen of culture supernatants 
(designated as 2G3 and 3F9). The 2G3 clones which 
exhibited  good  growth  characteristics  and  antibody 
production were subjected to subcloning. Antibodies 
secreted by the 2G3 clones were found to be IgG iso-
type. The specificity of the mAbs against NPM-mA 
was assessed by indirect ELISA, and the mAbs were 
able to react with both NPM-wt and NPM-mA. 
3.5 Immunohistochemical staining for the cases 
with NPM1 mutations 
Ten AML samples had been confirmed to bear 
NPM-mA by direct sequencing (data not shown). To 
validate the mAbs against NPM-mA as a diagnostic 
tool  for  AML  patients,  bone  marrow  or  peripheral 
blood samples were analyzed by IHC, using the 2G3 
mAb. The cytoplasmic dislocation of NPM1 was ob-
served  in  all  10  samples  with  NPM1  mutations, 
without staining in the cytoplasm of leukemic blasts 
in the negative control. Figure 4 shows representative 
results from a NPMc+AML patient. Int. J. Med. Sci. 2011, 8 
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Figure 4. Immunohistochemistry analyses of NPMc+AML samples using the 2G3 mAb. A, The cytoplasmic dislocation of 
NPM1 protein was observed in a representative bone marrow smear from NPMc+AML patients. Brownblack coarse 
granules in the cytoplasm of leukemic cells are shown. B, Negative control; the bone marrow from the same case as in (A) 
was stained with PBS substituting for the 2G3 mAb. 
 
 
4. Discussion 
Mutations  involving  the  NPM1  gene  are  the 
most frequent genetic aberrations of AML, and define 
a  clinically  distinct  subset  of  AML  [21,  22].  NPM1 
gene mutations always result in cytoplasmic disloca-
tion  of  NPM1,  which  is  the  immunohistochemical 
hallmark  of  NPMc+AML.  Immunohistochemistry 
may  be  a  simple,  rapid  screening  test  for  putative 
NPM1  gene  alterations  in  a  wide  range  of  human 
hematological malignancies [17, 21]. The crucial step 
of  immunohistochemical  detection  is  to  generate 
mAbs directed against NPM1 mutants. 
Currently,  immunohistochemistry  is  usually 
performed with mAbs that recognize wild-type and 
mutated  NPM1  proteins.  In  the  present  study,  we 
attempted  to  prepare  mAbs  against  NPM-mA.  The 
specific mAbs reacting with NPM-mA have the ad-
vantage of directly detecting the NPM-mA protein in 
leukemic cells. Firstly, some technical factors, such as 
NPM1 diffusion during tissue fixation and the use of 
different fixatives, may result in the incomplete con-
cordance between NPMc+ and NPM mutations status 
in some cases [20, 23]. Furthermore, because NPM1 is 
a  nuclear-cytoplasmic  shuttling  protein  and  highly 
expressive in proliferative cells, the small fraction of 
NPM-wt  protein  may  pathologically  present  in  the 
cytoplasm of tumor cells [24]. As a result, IHC label-
ing  with  the  mAbs  against  NPM-mA  and  NPM-wt 
may detect the NPM-wt existing in the cytoplasm and 
cause false positives. In this study, we analyzed the 
antigen epitope of NPM-mA protein and confirmed it 
may exist in the C-terminal domain of the NPM-mA 
by  using  the  Protean  module  of  DNAstar  analysis 
software. However, our results revealed that the ob-
tained mAbs did cross-react with NPM-wt. A possible 
explanation is that the distinction between NPM-mA 
and NPM-wt is small (only a tetranucleotide insertion 
located at the C-terminus of NPM-mA) [25]. So the 
2G3 mAb we obtained may not interat with a specific 
epitope generated by the NPM1 mutation. Recently, 
Gruszka  et  al  [26]  have  raised  a  mAb  (T26)  only 
against NPM1 mutants by using a 19-aminoacid pol-
ypeptide  immunogen  (CLAVEEVLSRK)  containing 
the  unique  C-terminus  of  the  NPM-mA  protein.  It 
indicated that the specific polypeptide generated by 
the C-terminus of the NPM1 (type A) mutation may 
be an optimal immunogen. 
Over  the  past  five  years,  IHC  detection  of 
NPMc+  on  bone  marrow  biopsies  has  been  widely 
carried out. However, as bone marrow biopsies are 
not always performed for the diagnosis of AML, es-
pecially in developing countries, to detect NPMc+ on 
bone marrow smears would be more advantageous. 
IHC assay was performed using the 2G3 mAb on bone 
marrow/peripheral blood smears of 10 AML patients 
with NPM-mA, and significant correlation was found 
between NPMc+ and NPM1 mutations status, which 
is  not  consistent  with  the  finding  of Mattsson  et al 
[27].  They  reported  that  the  immunocytochemical 
staining should not be used as a surrogate for NPM1 
mutations in AML, due to the high false positive and 
negative rates for NPMc+ in cell smears. The possible 
reasons for the two different results include the dif-Int. J. Med. Sci. 2011, 8 
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ferent anti-NPM antibodies (2G3 mAb or NA24 mAb) 
and the different method used (SP method or immu-
noalkaline phosphatase method). 
In summary, we put forward the production of 
mAbs that specifically recognize NPM1. Although the 
mAbs prove to react with NPM-mA and NPM-wt, this 
result provides valuable information in that the mAbs 
against NPM-mA cannot be raised using the recom-
binant  NPM-mA  protein  as  immunogen.  Further-
more, the complete correlation between NPMc+ in cell 
smears and NPM1 mutations status has been found in 
clinical samples by IHC using the 2G3, which would 
be  utilized  for  other  potential  techniques,such  as 
immunofluorescence, flow cytometry, etc. 
Acknowledgements 
We would like to thank Dr. Falini B in University 
of Perugia for the gift of pEGFP-C1-NPM-mA vectors. 
This project was supported by a grant from National 
Natural Science Foundation of China (No. 30872418) 
and Natural Science Foundation Project of CQ CSTC 
(No. 2010BB5363). 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Borer RA, Lehner CF, Eppenberger HM, et al. Major nucleolar 
proteins shuttle between nucleus and cytoplasm. Cell. 1989; 56: 
379-90. 
2.  Nishimura Y, Ohkubo T, Furuichi Y, et al. Tryptophans 286 and 
288 in the C-terminal region of protein B23.1 are important for 
its nucleolar localization. Biosci Biotechnol Biochem. 2002; 66: 
2239-42. 
3.  Schnittger  S,  Schoch  C,  Kern  W,  et  al.  Nucleophosmin  gene 
mutations are predictors of favorable prognosis in acute mye-
logenous leukemia with a normal karyotype. Blood. 2005; 106: 
3733-9. 
4.  Boissel  N,  Renneville  A,  Biggio  V,  et  al.  Prevalence,  clinical 
profile, and prognosis of NPM mutations in AML with normal 
karyotype. Blood. 2005; 106: 3618-20. 
5.  Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia 
carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): 
biologic and clinical features. Blood. 2007; 109: 874-85. 
6.  Liso A, Bogliolo A, Freschi V, et al. In human genome, genera-
tion  of  a  nuclear  export  signal  through  duplication  appears 
unique to nucleophosmin (NPM1) mutations and is restricted 
to AML. Leukemia. 2008; 22: 1285-9. 
7.  Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif 
and mutated tryptophan(s) are crucial for aberrant nuclear ex-
port  of  nucleophosmin  leukemic  mutants  in  NPMc+  AML. 
Blood. 2006; 107: 4514-23. 
8.  Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in 
de novo acute myeloid leukemia: the age-dependent incidences 
and the stability during disease evolution. Cancer Res. 2006; 66: 
3310-6. 
9.  Palmisano M, Grafone T, Ottaviani E, et al. NPM1 mutations 
are more stable than FLT3 mutations during the course of dis-
ease in patients with acute myeloid leukemia. Haematologica. 
2007; 92:1268-9. 
10.  Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia 
with mutated nucleophosmin (NPM1): is it a distinct entity? 
Blood. 2011; 117: 1109-20. 
11.  Becker H, Marcucci G, Maharry K, et al. Favorable prognostic 
impact of NPM1 mutations in older patients with cytogenet-
ically normal de novo acute myeloid leukemia and associated 
gene-  and  microRNA-expression  signatures:  a  Cancer  and 
Leukemia Group B study. J Clin Oncol. 2010; 28: 596-604. 
12.  Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the 
World  Health  Organization  (WHO)  classification  of  myeloid 
neoplasms  and  acute  leukemia:  rationale  and  important 
changes. Blood. 2009; 114:937-51. 
13.  Pasqualucci  L,  Liso  A,  Martelli  MP,  et  al.  Mutated  nucleo-
phosmin detects clonal multilineage involvement in acute my-
eloid  leukemia:  Impact  on  WHO  classification.  Blood.  2006; 
108:4146-55. 
14.  Papadaki  C,  Dufour  A,  Seibl  M,  et  al.  Monitoring  minimal 
residual disease in acute myeloid leukaemia with NPM1 muta-
tions by quantitative PCR: clonal evolution is a limiting factor. 
Br J Haematol. 2009; 144: 517-23. 
15.  Noguera  NI,  Ammatuna  E,  Zangrilli  D,  et  al.  Simultaneous 
detection of NPM1 and FLT3-ITD mutations by capillary elec-
trophoresis  in  acute  myeloid  leukemia.  Leukemia.  2005; 
19:1479-82. 
16.  Falini  B,  Mason  DY.  Proteins  encoded  by  genes  involved  in 
chromosomal alterations in lymphoma and leukemia: clinical 
value of their detection by immunocytochemistry. Blood. 2002; 
99: 409-26. 
17.  Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin 
in acute myelogenous leukemia with a normal karyotype. N 
Engl J Med. 2005; 352: 254-66. 
18.  Falini  B,  Martelli  MP,  Bolli  N,  et  al.  Immunohistochemistry 
predicts  nucleophosmin  (NPM)  mutations  in  acute  myeloid 
leukemia. Blood. 2006; 108:1999-2005. 
19.  Cordell JL, Pulford KA, Bigerna B, et al. Detection of normal 
and chimeric nucleophosmin in human cells. Blood. 1999; 93: 
632-42. 
20.  Konoplev S, Huang X, Drabkin HA, et al. Cytoplasmic locali-
zation of nucleophosmin in bone marrow blasts of acute mye-
loid  leukemia  patients  is  not  completely  concordant  with 
NPM1  mutation  and  is  not  predictive  of  prognosis.  Cancer. 
2009; 115: 4737-44. 
21.  Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic 
impact of NPM1 mutations in 1485 adult patients with acute 
myeloid leukemia (AML). Blood. 2006; 107: 4011-20. 
22.  Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia 
with  mutated  NPM1:  diagnosis,  prognosis  and  therapeutic 
perspectives. Curr Opin Oncol. 2009; 21: 573-81. 
23.  Falini B, Martelli MP, Pileri SA, et al. Molecular and alternative 
methods for diagnosis of acute myeloid leukemia with mutated 
NPM1: flexibility may help. Haematologica. 2010; 95: 529-34. 
24.  Ochs R, Lischwe M, O'Leary P, et al. Localization of nucleolar 
phosphoproteins  B23  and  C23  during  mitosis.  Exp  Cell  Res. 
1983; 146:139-49. 
25.  Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport 
in  acute  myeloid  leukaemia  with  mutated  NPM1:  molecular 
basis and clinical implications. Leukemia. 2009; 23:1731-43. 
26.  Gruszka AM, Lavorgna S, Consalvo MI, et al. A monoclonal 
antibody  against  mutated  nucleophosmin1  for  the  molecular 
diagnosis  of  acute  myeloid  leukemias.  Blood.  2010;  116: 
2096-102. 
27.  Mattsson G, Turner SH, Cordell J, et al. Can cytoplasmic nu-
cleophosmin be detected by immunocytochemical staining of 
cell smears in acute myeloid leukemia? Haematologica. 2010; 
95: 670-3. 